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tTruth lies within a little and certain compass, but error is
immense. (1)
he best known story about the Cynic philosopher Dio-
enes is of him carrying a lighted lantern in broad daylight
hrough the streets of Athens searching for an honest man.
he legend suggests a tortured trek where personal view-
oints were valued more highly than scientifically proven
ndings. In an analogous fashion, while acute myocardial
nfarction is one of the more widely studied disease states,
here remains a lack of clarity concerning the myriad of
anagement strategies espoused over the years. The clini-
ian thus is beset with an array of decision points, compli-
ated by both antecedent events and subsequent options that
onstrain potential choices (Fig. 1). Collet et al. (2) ad-
ressed this complexity of intertwined options in this issue
f the Journal, specifically focusing on cardiac catheteriza-
ion subsequent to fibrinolysis.
See page 1326
Clinical trials of fibrinolysis as first-line therapy in acute
T-segment elevation myocardial infarction (STEMI) have
emonstrated clinical benefit when therapy is administered
ithin 12 h of symptom onset (3). An alternative approach,
rimary (or direct) percutaneous coronary intervention
PCI) during acute STEMI, has demonstrable superiority
o fibrinolysis in virtually all studies of this approach (4).
nfortunately, resource constraints, availability, access, and
he logistics of emergency patient transport dictate that
any patients will be ineligible for primary PCI, particularly
ithin the 90-min window recommended by current guide-
ines. Fibrinolytic therapy remains the most widely used
eperfusion therapy in the world; even in the U.S., a large
roportion of acute STEMI patients are still primarily
reated with fibrinolytic therapy (5). Although the decision
o refer a patient for primary PCI is a singular (and
ell-studied) decision point, management of the patient
ubsequent to fibrinolysis vis-á-vis the intent and timing of
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.r
From the Division of Cardiovascular Medicine, Department of Medicine, Duke
niversity Medical Center, Durham, North Carolina.ardiac catheterization remains complex, imprecise, and less
ystematically studied.
As successful implementation of an appropriate manage-
ent strategy after fibrinolysis is a key to subsequent
ecovery, a plethora of options inevitably results in a lack of
onsistency in process and, by extension, suboptimal patient
utcomes. The analysis by Collet et al. (2) attempts to
iscern the “truth” via a unique approach: the assembly of a
ollection of related meta-analyses, with each meta-analysis
emaining true to proper inclusion and exclusion criteria for
eta-analytic reporting. In doing so, the authors have
voided the trap of comparing multiple different strategies
ead to head via one single, overall meta-analysis. However,
ecause the series of complex condition- and time-
ependent decisions demands an algorithmic, decision-tree
pproach, collecting multiple meta-analyses under an um-
rella concept (catheterization after fibrinolysis) was neces-
arily required to remain true to the clinical situation. An
pt description is that the authors are providing guidance
long the path of the search for “truth”; although the report
s nominally structured around 3 specific comparisons, in
eality the approach is designed to produce an overall “best
ractice” algorithm of care.
Delving into the details of the report, 3 specific meta-
nalyses were constructed, addressing the following explicit
uestions. First, should rescue PCI be performed on an
mergency basis whenever reperfusion failure is suspected?
econd, is an “early aggressive” or “early conservative”
pproach (i.e., cardiac catheterization within 24 h of fibri-
olysis vs. a delayed and/or ischemia-guided strategy) better
fter (presumed successful) clinical reperfusion? And third,
hould fibrinolytic therapy be administered to facilitate
rimary PCI (i.e., fibrinolysis on the way to the catheter-
zation laboratory)? As a subplot, analyses were stratified per
nterventional era, specifically the “balloon era” and the
stent era.”
Taken from the perspective of the stepwise decision
ptions illustrated in Figure 1, the first of the questions is
ctually the role of fibrinolysis in facilitating emergency
CI. The concept of facilitated PCI is straightforward—to
educe “door-to-patency” time in a proportion of patients,
hereby improving outcomes of the entire population. Rep-
esented as “Decision B” in Figure 1, the issues can be
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October 3, 2006:1336–8 Editorial Commentistilled to the following: 1) can the patient undergo
mergency primary PCI; and 2) if the answer is “yes,”
hould the patient be given fibrinolytic therapy on the way
o the catheterization suite? Whereas studies of facilitated
CI have documented infarct-related artery patency rates of
0% to 59% (6–8), an overall detrimental effect was
bserved in patients receiving fibrinolysis. In the report, a
ortality trend along with a significant difference in rein-
arction favoring primary PCI alone (p  0.0076) was
dentified. Note that the authors (appropriately) elected not
o analyze the question of primary PCI versus conventional
not facilitated) fibrinolysis (Fig. 1, Decision A). Seminal
rials including DANAMI-2 (Danish Trial in Acute Myo-
ardial Infarction-2) and PRAGUE-2 (PRimary Angio-
lasty in patients transferred from General community
ospitals to specialized PTCA Units with or without
mergency thrombolysis-2) have demonstrated the superi-
rity of primary PCI over conventional fibrinolysis, and
ther trials have provided remarkably consistent findings
4). Taken together, the answer to the first clinical dilemma
ppears quite clear: fibrinolytic therapy has no role when
rimary PCI can be accomplished. Note that adjunctive
acilitation with alternative agents, particularly blockade of
he platelet adenosine diphosphate receptor and the glyco-
rotein IIb/IIIa integrin, remains promising and thus de-
erves further study—these agents thus should not be
rouped (via meta-analysis) with studies of fibrinolytic
herapy.
Should primary fibrinolysis be preferred, a critical deci-
ion point follows shortly after the administration of fi-
rinolytic therapy dependent on whether clinical reperfu-
ion has been achieved (Fig. 1, Decisions C and D). The
igure 1. Flow diagram illustrating cardiac catheterization (Cath) decisio
llustrated in blue because it was not evaluated in the report of Collet et a
TEMI  ST-segment elevation myocardial infarction.econd meta-analysis (rescue PCI for failed fibrinolysis) trovides clarity concerning Decision C: whether to refer a
atient for rescue PCI. Again, the concept is straightfor-
ard; emergency mechanical reperfusion in patients failing
o reperfuse will provide additional incremental benefit
ompared with leaving the artery closed. Interestingly,
hereas rescue PCI is a class I recommendation per the
urrent American College of Cardiology/American Heart
ssociation guidelines (9) in patients who develop shock or
ave severe heart failure, for patients without shock, rescue
CI is considered a IIa (level of evidence C) indication.
his latter recommendation stems largely from “balloon
ra” studies where rescue PCI failed to reduce mortality
10,11). Collet et al. (2) demonstrated a strong trend at 30
ays in mortality reduction favoring rescue PCI (p 0.055)
long with a statistically significant reduction in death and
einfarction. At long-term follow-up, an overall 34% rela-
ive risk reduction again favored rescue PCI. The newfound
dvantage of rescue PCI was driven by the more recent
stent era” trials. Although this might superficially appear to
e an endorsement of stent over balloon technologies,
hanges in the pharmacotherapeutic environment, including
he liberal use of thienopyridine and glycoprotein IIb/IIIa
ntegrin blockade therapies, undoubtedly contribute. Fi-
ally, although bleeding was increased in the rescue arm,
his did not appear to contribute to mortality. Thus, the
eport supports the global use of rescue PCI in patients
ailing fibrinolysis. The decision to refer a patient to the
atheterization suite should be made early and resources
obilized expeditiously whenever this circumstance is iden-
ified.
While the elements of the decision tree to this point have
een categorical, there are a number of permutations related
ints in acute myocardial infarction (see text for details). (Decision A is
in this issue of the Journal.) PCI  percutaneous coronary intervention;n poo cardiac catheterization of the patient who has (presum-
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Editorial Comment October 3, 2006:1336–8bly) reperfused. Should the patient undergo catheteriza-
ion? When should catheterization be performed? Should
atheterization be delayed until the artery stabilizes? Should
atheterization be performed only in higher-risk patients?
nterestingly, routine catheterization is again considered a
lass IIb indication in the guidelines (9). With the report,
larity again is shed on this issue. Early systematic cathe-
erization after fibrinolysis in the “balloon era” was associ-
ted with worse outcomes favoring the conservative ap-
roach. These findings are largely reversed in the “stent era,”
ith outcomes favoring early and systematic cardiac cathe-
erization with revascularization. With balloon PCI, high
ates of thrombosis, recurrent myocardial infarction, and
estenosis were the norm; in the “stent era,” these issues
ave been largely addressed through the combination of
tent implantation and improved pharmacotherapy. Thus, if
he cardiology community were still practicing “balloon era”
ntervention, a delayed, ischemia-driven approach would be
ppropriate. Fortunately for patients, the “stent era” data
upports the use of early and systematic catheterization,
ith an approximate 42% relative risk reduction in death or
yocardial infarction at 30 days. Combining balloon and
tent data to reach a single conclusion via meta-analysis
ould thus have not only been inappropriate but clinically
nachronistic. The authors have shown that early systematic
atheterization with stenting to be the appropriate, modern
herapeutic strategy. The ultimate ramification of this find-
ng is that regardless of success or failure of fibrinolysis,
atients with an acute STEMI should be transferred to a
ertiary referral center for cardiac catheterization as soon as
ossible, with the decision to proceed to catheterization
anaged by the interventional cardiologist, and not the
acility of patient origin.
In conclusion, meta-analysis can, when constructed and
pplied appropriately, help guide serial clinical decisions,
ven when smaller and dissimilar studies address only a
imited scope of the decision tree and are individually
nderpowered to be definitive. Combining the consensus
bout primary PCI with the findings of the meta-analyses
resented herein, we believe the decision points illustrated
n Figure 1 to have the following answers:
. Fibrinolytic therapy should not be administered before
primary PCI.
. Fibrinolytic therapy should be administered when refer-
ral for primary PCI is not a reasonable (or available)
option.
. After fibrinolysis, emergency referral for rescue PCI is
indicated for fibrinolysis failure.
. After fibrinolysis, systematic referral for “urgent” cardiac
catheterization (within 24 h) is indicated even after
clinically successful fibrinolysis.. Stent PCI (accompanied by modern pharmacotherapy)
is preferable to balloon PCI.
atient management is rarely straightforward, typically con-
isting of a sequence of decisions, with dependencies on
oth preceding decisions and downstream capabilities. The
ork of Collet et al. (2) has clearly and succinctly illumi-
ated the path of the search for “truth” in the management
f the patient with an acute STEMI.
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